VRNA vs. ARCC
Compare and contrast key facts about Verona Pharma plc (VRNA) and Ares Capital Corporation (ARCC).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: VRNA or ARCC.
Correlation
The correlation between VRNA and ARCC is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
VRNA vs. ARCC - Performance Comparison
Key characteristics
VRNA:
4.75
ARCC:
2.17
VRNA:
4.78
ARCC:
2.91
VRNA:
1.56
ARCC:
1.39
VRNA:
4.78
ARCC:
3.80
VRNA:
22.86
ARCC:
15.85
VRNA:
11.73%
ARCC:
1.67%
VRNA:
56.45%
ARCC:
12.21%
VRNA:
-89.71%
ARCC:
-79.36%
VRNA:
0.00%
ARCC:
-1.93%
Fundamentals
VRNA:
$5.25B
ARCC:
$15.68B
VRNA:
-$2.08
ARCC:
$2.44
VRNA:
0.00
ARCC:
3.95
VRNA:
$5.62M
ARCC:
$2.77B
VRNA:
$4.55M
ARCC:
$2.61B
VRNA:
-$110.96M
ARCC:
$703.00M
Returns By Period
In the year-to-date period, VRNA achieves a 38.35% return, which is significantly higher than ARCC's 6.67% return.
VRNA
38.35%
23.82%
133.89%
273.55%
57.45%
N/A
ARCC
6.67%
0.73%
17.59%
27.00%
14.75%
13.70%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
VRNA vs. ARCC — Risk-Adjusted Performance Rank
VRNA
ARCC
VRNA vs. ARCC - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Ares Capital Corporation (ARCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
VRNA vs. ARCC - Dividend Comparison
VRNA has not paid dividends to shareholders, while ARCC's dividend yield for the trailing twelve months is around 8.22%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARCC Ares Capital Corporation | 8.22% | 8.77% | 9.59% | 10.12% | 7.65% | 9.47% | 9.01% | 9.88% | 9.67% | 9.22% | 11.02% | 10.06% |
Drawdowns
VRNA vs. ARCC - Drawdown Comparison
The maximum VRNA drawdown since its inception was -89.71%, which is greater than ARCC's maximum drawdown of -79.36%. Use the drawdown chart below to compare losses from any high point for VRNA and ARCC. For additional features, visit the drawdowns tool.
Volatility
VRNA vs. ARCC - Volatility Comparison
Verona Pharma plc (VRNA) has a higher volatility of 11.40% compared to Ares Capital Corporation (ARCC) at 4.83%. This indicates that VRNA's price experiences larger fluctuations and is considered to be riskier than ARCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
VRNA vs. ARCC - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and Ares Capital Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities